Lumos Diagnostics Expands FebriDx® Use to Pediatric Settings with BARDA Support - TipRanks.com
Summary
Lumos Diagnostics announced a BARDA-supported clinical study to expand FebriDx use in pediatric patients aged 2-12 in CLIA-waived settings. The company says the study could broaden its U.S. market significantly and open access to many more clinical sites. Lumos focuses on rapid point-of-care diagnostic technology, assay development, and digital reader platforms for infectious and inflammatory diseases. The update centers on commercial expansion of a healthcare diagnostics product rather than a new software release.
Classifications
industries
HealthTech
applications
Data Management
AskAI Classifications
Labels
No AI classifications detected